# Simultaneous RZV and aIIV4 Vaccination

> **NCT05007041** · PHASE4 · COMPLETED · sponsor: **Duke University** · enrollment: 267 (actual)

## Conditions studied

- Pain
- Quality of Life
- Injection Site Reaction
- Adverse Drug Event

## Interventions

- **BIOLOGICAL:** FLUAD® Quadrivalent
- **BIOLOGICAL:** Fluzone® High-Dose Quadrivalent
- **BIOLOGICAL:** SHINGRIX®

## Key facts

- **NCT ID:** NCT05007041
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-21
- **Primary completion:** 2023-03-04
- **Final completion:** 2023-06-08
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2024-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05007041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05007041, "Simultaneous RZV and aIIV4 Vaccination". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05007041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*